Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have substantially improved outcomes in multiple malignancies, but they may also trigger dysregulated immune activation accompanied by systemic toxic effects and multi-organ injury.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
